Confirm indication matches policy before requesting prior authorization

Coronary CTA is medically appropriate only for indications listed in this policy; when requesting prior authorization, confirm the requested CCTA aligns with one of the covered clinical scenarios in the policy (e.g., new/recurrent/worsening cardiac chest pain, specified structural or preoperative indications, congenital indications, post‑TAVR concerns).

• Ensure indication maps to policy language before submission.
• Requests that do not match listed indications may be denied.

Prior authorization required — newly diagnosed HF/cardiomyopathy

Prior authorization is required for CCT/CCTA to evaluate newly diagnosed congestive heart failure or cardiomyopathy only when ALL listed conditions are met: no prior history of CAD; ejection fraction <50%; low or intermediate pre‑test probability; no contraindications to CCTA; and no cardiac cath, SPECT, PET, or stress echocardiogram performed since diagnosis.

• Document absence of prior CAD and EF <50%.
• Document that no invasive/noninvasive ischemic testing (cardiac cath, SPECT, PET, or stress echo) has been done since diagnosis.

Specify the exact covered indication on the authorization request

When obtaining prior authorization state the specific clinical indication for the exam (for example: newly diagnosed cardiomyopathy without prior ischemic evaluation; re‑do CABG planning to assess graft patency or LIMA/RIMA location; or CTO PCI planning), because authorization should reflect the particular covered indication.

• Use the precise indication text from the policy in the authorization request.
• Include supporting documentation that matches the named indication.

When replacing stress test for transplant preop, document prior testing and ETT inability

If substituting CCTA for an imaging stress test in preoperative assessment for planned liver or kidney transplant, prior authorization should include documentation of prior testing status and risk: an imaging stress test within one year (unless new symptoms/ECG changes) or documentation that the patient could not perform an ETT when intermediate‑risk criteria apply.

• State whether an imaging stress test was performed and its date.
• If no ETT was possible, document inability to perform ETT and relevant clinical risk factors.

Authorization may be needed for CT for cardiac structure/morphology indications

Prior authorization may be required when requesting CT of the heart for structural/morphologic indications such as cardiac vein identification for LV lead placement, pulmonary vein anatomy evaluation pre‑ or post‑PVI (including 3–6 months post‑ablation), or other structural planning uses.

• Identify the structural indication (e.g., LV lead planning, PVI anatomy) in the request.
• Attach prior echocardiogram or other relevant imaging if required by the indication.

Prior authorization should reflect congenital and TAVR-related indications

Cardiac CT/CCTA is considered medically appropriate for the congenital indications and TAVR‑related pre‑procedural assessments listed in the policy; prior authorization workflows should reflect these specific indications when applicable.

• For TAVR candidacy include CTA Chest/Abdomen/Pelvis or cardiac CT annulus measurements as indicated.
• For congenital indications indicate prior imaging status (e.g., prior catheterization where coronary arteries were not identified).

Prior authorization for post‑TAVR CT only for indeterminate/concerning TTE findings

For post‑TAVR cardiac CT, prior authorization should be requested only when TTE is indeterminate or raises concerns (valve thrombosis, infective endocarditis, structural degeneration) or when valve‑in‑valve or surgical redo AVR is being contemplated; routine surveillance and evaluation of incidental HALT/HAM are not medically necessary.

• Include TTE findings demonstrating indeterminate or concerning results.
• Do not request CT for routine surveillance or incidental HALT/HAM as those are considered not medically necessary.

Indicate contrast, equipment capability, and any advanced CCTA analyses on authorization

Prior authorization submissions should note that CCTA involves IV contrast, high‑resolution/high‑speed CT equipment and may include advanced software analyses (automated plaque quantification or FFR‑CT), as these factors can affect medical‑necessity review.

• Indicate whether IV contrast will be used and the scanner capability/heart‑rate control plan.
• If requesting software‑derived analyses (plaque quantification or FFR‑CT), specify that in the authorization.

Obtain prior authorization as required for listed CPT codes (75572–75580)

Certain CPT codes for cardiac CT/CCTA and software‑derived analyses are listed in the policy (e.g., 75572, 75573, 75574, 75577, 75580) and may be subject to product‑specific coverage decisions; obtain prior authorization per payer rules for these services when required.

• List the CPT code(s) for the requested service on the authorization.
• Confirm coverage for the member's product before scheduling.

Use policy CPT descriptions for billing; no separate prior‑auth code list stated

The policy enumerates CPT codes for cardiac CT/CCTA and software‑derived analyses but does not specify a separate authorization code list; use the policy's CPT descriptions when billing and follow payer authorization rules.

• Use CPT descriptions from the policy for coding and billing.
• Authorization requirements are product/payer dependent and are not tied to a distinct code list in the policy text.

Account for code updates (75577 added) when obtaining authorization and billing

Prior authorization and billing workflows should account for recent code edits; code 75577 was added to the policy history and should be considered in authorization and billing processes according to the member's product and contract.

• Update billing/authorization systems to include CPT 75577.
• Verify product‑specific coverage for the newly listed code prior to service.

Provide prior test results when symptoms persist after or tests are equivocal

CCTA is appropriate when symptoms persist after a normal stress test or when prior noninvasive testing is equivocal, borderline, abnormal, or discordant since symptom onset; document prior test results when requesting authorization.

• Provide dates/results of prior stress tests or noninvasive evaluations.
• If prior testing is equivocal or discordant, include that interpretation in the documentation.

Document dual goals when using CCTA instead of invasive angiography after unexplained SCA

For individuals recovered from unexplained sudden cardiac arrest, CCTA may be used in place of invasive coronary angiography when both: (1) confirmation of presence/absence of ischemic heart disease and (2) exclusion of an anomalous coronary artery are required; document both goals in the authorization.

• State that the study is replacing invasive angiography and document the need to confirm ischemic disease and exclude anomalous coronary anatomy.
• Attach prior resuscitation details and relevant contraindications to conventional angiography if present.

Document rationale when CCTA substitutes for stress imaging before class IC agents

When CCTA is used instead of stress imaging to evaluate structural heart disease before prescribing class IC antiarrhythmic agents (flecainide or propafenone), indicate this rationale and document why stress imaging was not performed.

• Specify the intended medication decision (class IC agent) in the request.
• Include rationale for using CCTA instead of stress imaging.

Document recent imaging stress test or new symptoms/ECG changes for high‑risk surgical candidates

High‑risk surgical candidates should have an imaging stress test within one year unless new cardiac symptoms or a new ECG change have occurred; if substituting CCTA, document the timing of the last stress test or new symptoms/ECG changes to justify replacement.

• Document date of last imaging stress test if within one year.
• If no recent stress test, document new symptoms or ECG changes that justify CCTA.

Include inconclusive echocardiogram report when requesting CT for structural indications

For structural cardiac CT indications that require prior echocardiography, the authorization should include evidence that an echocardiogram was performed and was inconclusive (e.g., for mass, thrombus, pericarditis, or post‑surgical complications).

• Attach the echocardiogram report showing inconclusive findings.
• State the specific structural indication that remains unresolved by echo.

Document MRI contraindication/unavailability when using CT as an alternative

When echocardiogram is inconclusive or MRI is contraindicated/unavailable for suspected ARVD/ARVC or post‑operative complications, document that MRI cannot be performed and that CT is the indicated alternative.

• Document MRI contraindication or unavailability.
• Provide clinical criteria supporting suspicion for ARVD/ARVC or the post‑operative complication.

When escalation from TTE to CT is needed, include TTE findings in the request

Escalation from an indeterminate or concerning TTE to cardiac CT is implied by the policy for post‑procedural or structural concerns; document the TTE findings that prompted escalation when requesting CT.

• Include the TTE report demonstrating indeterminate or concerning findings.
• Describe how CT will address the diagnostic gap left by TTE.

Guidelines and trials inform but do not add step‑therapy mandates in this excerpt

Clinical trials and guideline citations are provided in the policy for context, but the policy text in the provided segments does not impose additional step‑therapy mandates beyond the listed indications and imaging prerequisites.

• Do not assume additional step‑therapy requirements beyond those explicitly stated in the policy.
• Use guideline recommendations as clinical context when justifying requests.

No explicit step‑therapy pathway stated — follow policy criteria and payer rules

The policy excerpts provided do not describe an explicit step‑therapy pathway for CCTA; when no step therapy is stated, follow the policy's indication criteria and local payer prior authorization rules.

• If uncertain, confirm with the member's product/payer whether step requirements exist.
• Rely on explicit policy criteria (indications, prior test requirements) for clinical justification.

Document basis for medical necessity (guidelines, evidence, law, contract)

Medical necessity determinations are based on evidence‑based literature, national professional guidelines, federal/state law, regulatory mandates, and the member's subscriber contract language; include relevant references or contract notes in complex cases.

• Indicate guideline or evidence references when appropriate to support the request.
• Document any applicable regulatory or contractual factors for the member.

Include prior PCI/CABG or obstructive CAD history plus current symptoms

When requesting authorization for symptomatic patients with prior PCI/CABG or known obstructive CAD, include documentation of prior PCI/CABG or prior obstructive CAD and current symptomatic presentation (cardiac chest pain, anginal equivalents, or symptoms similar to prior ischemic episodes).

• Attach prior procedure reports (PCI/CABG) or prior CCTA/angiography showing obstructive CAD.
• Describe current symptoms and how they relate to prior ischemic episodes.

Document qualifying features when evaluating anomalous coronary arteries in <40 y/o

For individuals under age 40 being evaluated for anomalous coronary arteries, document qualifying clinical features such as exertional syncope, persistent exertional chest pain with a normal stress test, a full sibling with sudden death before age 40 or documented anomalous coronary artery, or resuscitated sudden death.

• Provide family history or sibling sudden death documentation if applicable.
• Attach stress test results if chest pain is exertional with normal stress test.

Document clinical features suggestive of systemic vasculitis for coronary assessment

When requesting CCTA for suspected coronary involvement from systemic vasculitis, include documentation of clinical features suggestive of vasculitis (e.g., unexplained elevated inflammatory markers, constitutional symptoms, or multiple visceral infarcts without embolic etiology).

• Attach lab results (ESR, CRP) and descriptions of constitutional symptoms.
• Provide imaging or clinical evidence of visceral infarcts if present.

Document timing of left main stent (6–12 months) for one‑time surveillance CCTA

To justify a one‑time CCTA evaluation for left main stent surveillance, document timing of prior left main stent placement to show the exam falls within the 6–12 month window specified by the policy.

• Include procedure date and operative/PCI report showing left main stent placement.
• State that this is a one‑time evaluation at 6–12 months post‑stent per policy.

Document inability to perform ETT and prior stress test timing for transplant preop CCTA

For transplant preoperative CCTA in place of stress testing, document the patient's inability to perform an exercise treadmill test (ETT) when intermediate‑risk surgery criteria apply and include the date of the last imaging stress test if within one year.

• Document inability to perform ETT and clinical risk factors that qualify for intermediate‑risk assessment.
• Provide date of last imaging stress test if available.

Attach inconclusive echocardiogram report when requesting CT for structural indications

When CT is requested for specific structural indications (mass, thrombus, pericarditis, post‑surgical complications), include the echocardiogram report showing it was performed and inconclusive, as this is required for cardiac CT coverage for these indications.

• Attach the echocardiogram report and note the inconclusive elements.
• Explain why CT is necessary to resolve the diagnostic question.

Support TAVR pre‑op CT requests with specific study type and clinical rationale

For TAVR pre‑procedural imaging, documentation should support use of CTA Chest/Abdomen/Pelvis, cardiac CT annulus measurements, or coronary CTA in lieu of catheterization — include the specific study requested and the clinical rationale when submitting authorization.

• Specify which TAVR‑related CT study is requested (CTA Chest/Abdomen/Pelvis, cardiac CT annulus measurement, coronary CTA).
• Provide clinical justification for using CT instead of catheterization when applicable.

Include prior cath/CCTA showing stenosis or FFR thresholds when documenting CAD status

When documenting obstructive or non‑obstructive CAD to support CCTA use or downstream decisions, include prior heart catheterization or CCTA results showing the stenosis thresholds or FFR values cited in policy (e.g., ≥40% left main, ≥50% other major epicardial vessels, or FFR ≤0.80) or history of prior PCI/CABG.

• Attach prior cath or CCTA reports with percent stenosis or FFR values.
• If prior revascularization present, include procedure reports (PCI/CABG).

Describe ischemic symptom type and prior CABG/PCI; document premedication/HR control

Document the nature of ischemic‑evaluation symptoms (likely anginal, less likely anginal, or anginal equivalents) and any prior history of CABG or PCI when ordering CCTA; also document premedication or heart‑rate control if used for image acquisition.

• Describe symptom pattern consistent with policy definitions (e.g., exertional chest pain relieved by rest/nitro).
• Note any heart‑rate control measures (beta‑blocker use) used for image quality.

Reference FDA device/contrast regulatory information when relevant

Refer to the FDA Medical Device website for regulatory status and recall information relevant to CT hardware and contrast agents used for cardiac CTA; include device/contrast regulatory notes if relevant to the authorization or safety review.

• If device or contrast safety concerns are relevant, reference FDA device/recall information.
• Include device model or contrast agent details if requested by payer.

Use policy CPT descriptions for billing and confirm product coverage

Use CPT codes and descriptions listed in the policy when billing cardiac CT/CCTA and derived analyses; note that additional payer documentation requirements may apply and coverage can vary by product.

• Code the service using the CPT codes enumerated (e.g., 75572–75580 as applicable).
• Confirm product‑level coverage before billing; include any required documentation with claims.

Verify member product coverage and include supporting documentation

Demonstrate that the member's product covers the requested service and include documentation that policy criteria are met when required; services may be denied if the product does not cover the service even when policy criteria are satisfied.

• Verify member product benefit for the requested CT service before authorization.
• Include product coverage confirmation and policy‑criteria documentation in the request.

Denial risk if requested indication does not match listed covered scenarios

Requests for CCTA that do not match the policy's listed clinical indications (new, recurrent, or worsening cardiac chest pain or the other specified scenarios) are at risk for denial; ensure the submitted indication and documentation directly align with a covered scenario.

• Map the clinical presentation to the exact policy indication.
• If the patient’s symptoms have a likely non‑cardiac explanation, do not request CCTA for ischemic evaluation.

Prior advanced testing since diagnosis may preclude CCTA for newly diagnosed HF/cardiomyopathy

If cardiac catheterization, SPECT, cardiac PET, or stress echocardiogram has been performed since diagnosis of heart failure/cardiomyopathy, that prior testing negates the policy criterion for using CCTA in newly diagnosed disease and may lead to denial.

• Include dates and results of any post‑diagnosis invasive or advanced noninvasive ischemic testing.
• If such testing exists since diagnosis, do not submit CCTA under the newly diagnosed HF/cardiomyopathy indication.

Plaque quantification requests may be denied in multiple excluded scenarios

Requests for coronary CTA plaque quantification or plaque analysis will be denied as not medically necessary when performed for unstable coronary syndromes; in conjunction with invasive coronary catheterization; for screening or surveillance; within 30 days post‑MI; or when current CCTA is normal, CAD‑RADS‑0, shows high‑grade stenosis (>70%), CAD‑RADS 4, or CAD‑RADS 5.

• Do not request plaque quantification for unstable coronary syndromes or within 30 days of MI.
• If current CCTA documents high‑grade stenosis, CAD‑RADS 4/5, or normal CCTA/CAD‑RADS‑0, plaque quantification is not medically necessary.

Failure to obtain recommended follow‑up after 45‑day LAA imaging may risk later denials

If a 45‑day post‑LAA occlusion imaging study documents a peri‑device gap ≥5 mm or device‑related thrombus and a follow‑up imaging interval was indicated (usually 3–6 months), failure to obtain the recommended repeat imaging may render later imaging requests unsupported.

• Provide prior 45‑day imaging results and any follow‑up imaging performed.
• If 45‑day imaging showed peri‑device gap ≥5 mm or thrombus, include documentation of subsequent imaging at the recommended interval.

Routine post‑TAVR surveillance and incidental HALT/HAM evaluations are not covered

Cardiac CT for routine surveillance or follow‑up post‑TAVR, including evaluation of incidental HALT/HAM, is considered not medically necessary and requests for such routine surveillance may be denied.

• Do not submit routine surveillance CT post‑TAVR or CT to evaluate incidental HALT/HAM.
• If CT is requested post‑TAVR, document specific TTE concerns that meet the policy criteria.

Document non‑cardiac explanations for symptoms; these may justify denying CCTA

If the patient's symptoms have a non‑cardiac explanation that is the most likely cause (e.g., GERD, trauma, anemia, COPD, pleurisy), document that diagnosis; such cases may support denial of cardiac ischemic‑evaluation testing.

• Include evidence of the non‑cardiac diagnosis if applicable.
• If non‑cardiac cause is most likely, do not pursue CCTA for ischemic evaluation.

Verify product‑level code coverage — services may be denied if product excludes them

Coverage and denial decisions for codes may vary by member product; verify whether the member's product covers the CPT code(s) before submitting authorization because services may be denied if the product does not cover them.

• Confirm product‑level code coverage prior to authorization.
• If product excludes the service, the policy criteria do not apply and the request may be denied.

Code lists may change — verify current CPT/Category III updates with payer

AMA/CMS code updates may occur more frequently than policy revisions; the policy's code list may not be exhaustive — verify current CPT/Category III updates and payer code lists when preparing authorization and billing.

• Check for recent CPT or Category III code changes beyond the policy text.
• Confirm with payer if additional or replacement codes should be used.

Product coverage determines applicability of policy criteria — confirm before submitting

If the member's product does not cover a specific service, medical policy criteria do not apply and the request may be denied; ensure authorization and documentation reflect the member's contract and product rules.

• Confirm whether the member's commercial, Medicaid, or Medicare product covers the requested CT service.
• Document product coverage confirmation in the authorization when required.

Where policy is silent on authorization triggers, follow criteria and contact payer if unclear

When no specific authorization triggers or denial conditions are stated in policy text for a scenario, rely on the explicit covered‑indication criteria and payer rules; if uncertain, contact the payer for pre‑authorization guidance.

• Use explicit policy criteria to justify requests when authorization triggers are not defined.
• Contact payer for clarification when policy text is silent on authorization triggers.